Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2024 01:32 ET | Source: Recursion Pharmaceuticals

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
August 05, 2024 16:01 ET | Source: Recursion Pharmaceuticals

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
June 26, 2024 22:07 ET | Source: Recursion Pharmaceuticals

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
June 26, 2024 16:06 ET | Source: Recursion Pharmaceuticals

Recursion Announces Proposed Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
June 03, 2024 09:00 ET | Source: Recursion Pharmaceuticals

Recursion to Participate in Upcoming Investor Conferences

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
May 29, 2024 15:27 ET | Source: Recursion Pharmaceuticals

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
May 24, 2024 16:30 ET | Source: Recursion Pharmaceuticals

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert...
May 13, 2024 05:00 ET | Source: Recursion Pharmaceuticals

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion...
May 09, 2024 16:01 ET | Source: Recursion Pharmaceuticals

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will...
May 02, 2024 08:00 ET | Source: Recursion Pharmaceuticals

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...